In contrast, a large retrospective cohort study evaluated the risk of genital and urinary tract infections associated with SGLT2 inhibitors compared to DPP inhibitors, sulfonylureas and thiazolidinediones prescribed in addition to metformin in type 2 diabetes patients. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.